Collins Helen Louise

CHIEF MEDICAL OFFICEREnliven Therapeutics, Inc. (ELVN) · full profile →Form 4 · filed Mar 19, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$139K
Net Open-Market Flow
-$139K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 17, 2026Sell(S)5K$27.76$139K25K
Mar 17, 2026Option exercise(M)5K$2.48$12K30K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 17, 2026Option exercise(M)5K$0176K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001701247-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly: